CytoImmune Therapeutics to Present Preclinical Data Highlighting Potential of Novel TRACK-NK Cells to Selectively Target and Kill Hematologic and Solid Tumor Cancer Cells

MONROVIA, Calif.--(BUSINESS WIRE)--CytoImmune Therapeutics, a clinical-stage immuno-oncology company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, today announced new preclinical data highlighting the potential of the company’s tumor-reactive NK (TRACK-NK) cell program, CYTO-102, to potently and selectively kill tumor cells with the mechanism of...

Click to view original post